A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination With Chemotherapy in Subjects With Refractory or Recurrent Acute Myelogenous Leukemia (Protocol No. P07649 (005)).

Trial Profile

A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination With Chemotherapy in Subjects With Refractory or Recurrent Acute Myelogenous Leukemia (Protocol No. P07649 (005)).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs MK 8242 (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 02 Jun 2015 Results of the monotherapy dose-escalation phase in 26 patients (24 evaluable for response) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 29 Oct 2014 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.
    • 23 Jul 2014 Planned End Date changed from 1 Oct 2016 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top